TRELLIS BIOSCIENCE RAISES $9 MILLION TO ADVANCE CLINICAL DEVELOPMENT OF CALPURBATUG (TRL1068)

Funding will support continued development of Calpurbatug (TRL1068), a novel therapy being evaluated for prosthetic joint infections (PJI) REDWOOD CITY, Calif., July 16, 2026 /PRNewswire/ -- Trellis Bioscience, a clinical-stage biotechnology company developing native human monoclonal...